Bone pain palliation from osteoblastic metastases
For cancer that has spread widely to bone and causes pain everywhere at once, a bone-seeking radioactive injection travels to every affected spot in the skeleton and delivers pain-relieving radiation from the inside, sparing a trip to radiotherapy for each site.
Overview
Widespread osteoblastic (bone-forming) metastases, most often from prostate or breast cancer, can cause diffuse skeletal pain that is impractical to treat site-by-site with external beam radiotherapy. Systemically administered beta-emitting bone-seeking radiopharmaceuticals - strontium-89 chloride, samarium-153 lexidronam (153Sm-EDTMP) and, historically, phosphorus-32 sodium phosphate - concentrate at sites of increased osteoblastic turnover in proportion to bone remodelling activity, verified beforehand by a positive radionuclide bone scan, and deliver local beta radiation to relieve pain over one to a few weeks. The alpha-emitting radium-223 dichloride is a related but distinct case: as a calcium mimetic it also concentrates in osteoblastic bone lesions, but it is FDA- and EMA-approved specifically for castration-resistant prostate cancer with symptomatic bone metastases and no visceral disease, and, unlike the older beta emitters, it prolongs overall survival, not just pain.
The SNMMI/EANM procedure standard for these agents recommends 89Sr-chloride at roughly 148 MBq (or 1.5-2.2 MBq/kg), 153Sm-EDTMP at 37 MBq/kg, and 223Ra-dichloride at 55 kBq/kg every four weeks for six cycles; all three are given as a slow intravenous injection with attention to avoiding extravasation. Only 223Ra-dichloride has shown a survival benefit (from the ALSYMPCA trial); 89Sr and 153Sm are recommended solely for pain palliation and are not associated with any demonstrated survival advantage, and neither should be given to patients with a life expectancy under about four weeks because of a lag of days to weeks before pain relief.
Selection is straightforward but firm: patients need painful lesions that are osteoblastic (not lytic) and bone-scan-avid, adequate baseline blood counts because myelosuppression is the dose-limiting toxicity of the beta emitters in particular, and no impending spinal cord compression or pathological fracture risk, which need surgery or external beam radiotherapy instead. Concomitant bisphosphonates are not contraindicated. Weekly complete blood counts are recommended for eight weeks after treatment, or until recovery from the nadir, given the risk of cytopenias.
State of the art
- The SNMMI Procedure Standard/EANM Practice Guideline for radionuclide therapy of painful bone metastases (updated version discussed in 2023 SNMMI technologist literature) sets current dosing, patient selection and monitoring practice for 89Sr, 153Sm-EDTMP and 223Ra-dichloride, and notes that 32P sodium phosphate is no longer available for this use in the United States.
Show survival figures (2)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- Radium-223's approval, based on the phase 3 ALSYMPCA trial (median overall survival 14.9 vs 11.3 months for placebo), remains the only agent in this class with a demonstrated survival benefit; its US label is currently restricted to castration-resistant prostate cancer with symptomatic bone metastases and no visceral disease.
- About 60% of patients receiving radium-223 experience meaningful pain reduction, with an estimated 3-4 month survival extension reported across analyses of the pivotal trial population.
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- Bone metastases occur in a large majority of men who die of prostate cancer and a majority of women with metastatic breast cancer, and painful skeletal metastases are one of the most common causes of cancer-related pain requiring systemic, rather than site-specific, treatment.
Strontium-89 chloride or samarium-153-EDTMP for pain palliation; no proven survival benefit, and inappropriate if life expectancy is under about four weeks.
Radium-223 dichloride, six cycles at 55 kBq/kg every four weeks, chosen over the older beta emitters because it also improves overall survival and delays symptomatic skeletal events.
Confirm osteoblastic, bone-scan-avid lesions and adequate blood counts; exclude impending cord compression or pathological fracture, which need surgery or external beam radiotherapy instead.
Subtypes & biomarkers
topHow often this target appears
Dated changes read from the records linked to this indication: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
All 2 changes by month →What is in development for Bone pain palliation from osteoblastic metastases, drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Technologies being tested · 1
Open problems and what is being done
Strontium-89 and samarium-153 remain palliative only, with no survival benefit shown in any trial, and their future use may narrow further as radium-223 and lutetium-177-based radioligand therapies increasingly address the same castration-resistant prostate cancer population earlier in the disease course.
Myelosuppression from the beta emitters can delay or preclude subsequent chemotherapy, an important sequencing consideration in patients who may still be candidates for later systemic therapy.
Selecting between radium-223, PSMA-targeted lutetium-177 radioligand therapy and standard therapies in castration-resistant prostate cancer with bone-only disease is an active area of clinical judgement rather than settled guideline, particularly regarding sequencing and combination.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Direct links plus the targets, companies, and technologies of this cancer's products.
isotopes
4technologies
2drugs
3companies
3trials
1key papers
1Latest papers
topQuery for this indication: (TITLE:"Bone pain palliation from osteoblastic metastases" OR ABSTRACT:"Bone pain palliation from osteoblastic metastases") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Bone pain palliation from osteoblastic metastases, not a curated reading list.
Similar pages
not linked directly; found by shared links- AgentStrontium-89 chloride
Shares Strontium-89, Samarium-153, Samarium-153 lexidronam, Radium-223 dichloride and the tag beta emitter.
- TargetBone mineral (hydroxyapatite)
Shares Phosphorus-32 (radiophosphorus), Samarium-153, Samarium-153 lexidronam, Radium-223 dichloride.
- TermBone metastases and skeletal-related events
Shares Phosphorus-32, Strontium-89, Samarium-153, Radium-223 dichloride.
- TermFlare phenomenon
Shares Strontium-89, Samarium-153, Radium-223 dichloride, Radium-223.
- PersonKarim Fizazi
Shares ALSYMPCA, Radium-223 dichloride, Radium-223.
- IndicationOsteosarcoma
Shares Samarium-153, Radium-223 dichloride, Radium-223.
- PersonChris C. Parker
Shares ALSYMPCA: alpha emitter radium-223 and survival in metastatic prostate cancer with bone metastases, Radium-223.
- TechnologyMacropa chelation
Shares Radium-223 and the tag alpha therapy.